首页> 外文期刊>Journal of neurology >Cytarabine and highly active antiretroviral therapy in HIV-related progressive multifocal leukoencephalopathy.
【24h】

Cytarabine and highly active antiretroviral therapy in HIV-related progressive multifocal leukoencephalopathy.

机译:阿糖胞苷和高活性抗逆转录病毒疗法在HIV相关的进行性多灶性白质脑病中的应用。

获取原文
获取原文并翻译 | 示例
       

摘要

We assessed survival in AIDS-related progressive multifocal leukoencephalopathy (PML) and the effect of cytarabine and antiretroviral therapy in a retrospective analysis of a series of consecutive 35 patients with AIDS-related PML in an academic AIDS referral center over 15 years. Treatment regimens consisted of highly active antiretroviral treatment (HAART), intravenous cytarabine, or both. Median survival after diagnosis in the overall series was 88 days. Patients with low CD4 cell count tended to have shorter survival. Seven patients (20%) had prolonged survival (> 1 year). Cytarabine did not affect survival. Seven patients were treated with HAART, which did not significantly improve survival. We conclude that the prognosis of AIDS-related PML is still poor, with a median survival of 3 months.
机译:我们回顾性分析了15年来在学术性AIDS转诊中心连续进行的35例与AIDS相关的PML的患者的回顾性分析,评估了AIDS相关的进行性多灶性白质脑病(PML)的生存率以及阿糖胞苷和抗逆转录病毒治疗的效果。治疗方案包括高效抗逆转录病毒治疗(HAART),静脉注射阿糖胞苷或两者。在整个系列中,诊断后的中位生存期为88天。 CD4细胞计数低的患者往往生存期较短。七名患者(20%)具有延长的生存期(> 1年)。阿糖胞苷不影响生存。有7例患者接受了HAART治疗,但并未显着提高生存率。我们得出的结论是,与艾滋病相关的PML的预后仍然很差,中位生存期为3个月。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号